50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#123

Somatostatin

MetabolicSSTSRIFGrowth Hormone Inhibiting HormoneSomatotropin Release-Inhibiting Factor

A naturally occurring peptide hormone that inhibits the release of growth hormone, insulin, glucagon, and other hormones, with therapeutic applications in managing hormonal hypersecretion and gastrointestinal bleeding.

Share:

Overview

Somatostatin is a peptide hormone naturally produced by the hypothalamus, gastrointestinal tract (D cells), and pancreatic delta cells. It exists in two bioactive forms: somatostatin-14 (a 14-amino acid cyclic peptide) and somatostatin-28 (an N-terminally extended form). First identified by Roger Guillemin's laboratory in 1973 during efforts to isolate growth hormone-releasing factor, somatostatin was instead found to potently inhibit growth hormone release — earning it the name "growth hormone inhibiting hormone."

Somatostatin acts through five G-protein coupled receptor subtypes (SSTR1-5) distributed throughout the body. Its biological effects are broadly inhibitory: it suppresses the release of growth hormone from the pituitary, insulin and glucagon from the pancreas, gastrin and other gut hormones from the gastrointestinal tract, and thyroid-stimulating hormone. It also inhibits gastrointestinal motility, gastric acid secretion, pancreatic enzyme secretion, and splanchnic blood flow.

The therapeutic use of native somatostatin is limited by its extremely short half-life of approximately 1-3 minutes. This rapid degradation necessitates continuous intravenous infusion for clinical applications. To overcome this limitation, longer-acting synthetic analogs were developed, including octreotide (Sandostatin) and lanreotide (Somatuline), which have become mainstays of therapy for conditions involving hormonal hypersecretion such as acromegaly and neuroendocrine tumors.

Native somatostatin infusion is primarily used in acute clinical settings, particularly for the management of variceal bleeding (esophageal varices) and other gastrointestinal hemorrhage, where it reduces portal blood flow and splanchnic circulation. It is also used as a diagnostic tool and in the acute management of pancreatic fistulas and certain hormonal crises.

Research Uses & Applications

  • Acute management of variceal and upper gastrointestinal bleeding via IV infusion
  • Inhibition of growth hormone, insulin, and glucagon release in hypersecretory states
  • Management of pancreatic and enterocutaneous fistulas
  • Diagnostic applications in endocrine testing
  • Template molecule for development of therapeutic analogs (octreotide, lanreotide)
  • Research tool for studying hormonal regulation and receptor signaling

Key Research Findings

  • Clinical trials showed somatostatin infusion is effective in controlling acute variceal bleeding, comparable to endoscopic sclerotherapy in some studies.
  • Receptor subtype characterization studies identified five somatostatin receptor subtypes (SSTR1-5) with distinct tissue distributions and signaling properties.
  • Research demonstrated somatostatin's role in inhibiting angiogenesis and tumor cell proliferation through SSTR-mediated mechanisms.
  • Studies on somatostatin receptor imaging (using radiolabeled octreotide) revolutionized the diagnosis and management of neuroendocrine tumors.
  • Gene expression studies revealed somatostatin as a key regulator of the hypothalamic-pituitary axis and gastrointestinal endocrine function.

Risks & Side Effects

  • Very short half-life (1-3 minutes) requires continuous IV infusion, limiting practical use.
  • Rebound hormone hypersecretion can occur upon discontinuation of somatostatin infusion.
  • Hyperglycemia or hypoglycemia may occur due to effects on insulin and glucagon secretion.
  • Gastrointestinal side effects including nausea, abdominal cramps, and diarrhea.
  • Bradycardia and cardiac conduction abnormalities have been reported during infusion.

Administration

Administered by continuous intravenous infusion for acute indications. Typical dosing for variceal bleeding: 250 mcg IV bolus followed by 250 mcg/hour continuous infusion for up to 5 days. For pancreatic fistulas: 250 mcg/hour continuous infusion. Not suitable for subcutaneous or oral administration due to rapid degradation. Synthetic analogs (octreotide, lanreotide) are used for chronic therapy requiring longer duration of action.

Legal Status

Available as a prescription medication for hospital use in many countries. Synthetic somatostatin is less commercially prominent than its analogs (octreotide, lanreotide) due to the short half-life. Not available over-the-counter. Used primarily in inpatient settings.

Frequently Asked Questions

What is Somatostatin?

A naturally occurring peptide hormone that inhibits the release of growth hormone, insulin, glucagon, and other hormones, with therapeutic applications in managing hormonal hypersecretion and gastrointestinal bleeding.

What are the main uses of Somatostatin?

The primary research applications of Somatostatin include: Acute management of variceal and upper gastrointestinal bleeding via IV infusion; Inhibition of growth hormone, insulin, and glucagon release in hypersecretory states; Management of pancreatic and enterocutaneous fistulas; Diagnostic applications in endocrine testing; Template molecule for development of therapeutic analogs (octreotide, lanreotide); Research tool for studying hormonal regulation and receptor signaling.

What are the risks and side effects of Somatostatin?

Documented risks and side effects include: Very short half-life (1-3 minutes) requires continuous IV infusion, limiting practical use.; Rebound hormone hypersecretion can occur upon discontinuation of somatostatin infusion.; Hyperglycemia or hypoglycemia may occur due to effects on insulin and glucagon secretion.; Gastrointestinal side effects including nausea, abdominal cramps, and diarrhea.; Bradycardia and cardiac conduction abnormalities have been reported during infusion.. Always consult a healthcare professional before considering any peptide.

Is Somatostatin legal?

Available as a prescription medication for hospital use in many countries. Synthetic somatostatin is less commercially prominent than its analogs (octreotide, lanreotide) due to the short half-life. Not available over-the-counter. Used primarily in inpatient settings.

How is Somatostatin administered?

Administered by continuous intravenous infusion for acute indications. Typical dosing for variceal bleeding: 250 mcg IV bolus followed by 250 mcg/hour continuous infusion for up to 5 days. For pancreatic fistulas: 250 mcg/hour continuous infusion. Not suitable for subcutaneous or oral administration due to rapid degradation. Synthetic analogs (octreotide, lanreotide) are used for chronic therapy requiring longer duration of action.

Related Peptides

#29

GLP-1

Metabolic

#65

Octreotide

Metabolic

#66

Lanreotide

Metabolic

#67

Pasireotide

Metabolic

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #122 Colistin#124 Substance P →